New cream shows promise for painful hand and foot pustules

NCT ID NCT07013201

Recruiting now Disease control Sponsor: LEO Pharma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study tests a cream called delgocitinib for people with mild to severe palmoplantar pustulosis, a skin condition causing painful pus-filled blisters on hands and feet. About 135 adults will apply the cream twice daily for 16 weeks. The main goal is to see if the cream reduces symptoms by at least 75% compared to a placebo cream.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

palmoplantar pustulosis psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PALMOPLANTAR PUSTULOSIS

Contacts and locations

Locations

LEO Pharma Investigation Site
RECRUITING

Mayfield Heights, Ohio, 44124, United States
LEO Pharma Investigational Site
RECRUITING

Fountain Valley, California, 92708, United States
LEO Pharma Investigational Site
RECRUITING

Douglasville, Georgia, 30135, United States
LEO Pharma Investigational Site
RECRUITING

West Bloomfield, Michigan, 48322, United States
LEO Pharma Investigational Site
RECRUITING

Elmhurst, New York, 11373, United States
LEO Pharma Investigational Site
RECRUITING

Portland, Oregon, 97201, United States
LEO Pharma Investigational Site
RECRUITING

Philadelphia, Pennsylvania, 19103, United States
LEO Pharma Investigational Site
RECRUITING

Calgary, Alberta, T3A 2N1, Canada
LEO Pharma Investigational Site
RECRUITING

Surrey, British Columbia, V3R 6A7, Canada
LEO Pharma Investigational Site
RECRUITING

Winnipeg, Manitoba, R3M 3Z4, Canada
LEO Pharma Investigational Site
RECRUITING

Fredericton, New Brunswick, E3B 1G9, Canada
LEO Pharma Investigational Site
RECRUITING

Hamilton, Ontario, L8L 3C3, Canada
LEO Pharma Investigational Site
COMPLETED

Hamilton, Ontario, L8N 1Y2, Canada
LEO Pharma Investigational Site
RECRUITING

Markham, Ontario, L3P 1X2, Canada
LEO Pharma Investigational Site
RECRUITING

Waterloo, Ontario, N2J 1C4, Canada
LEO Pharma Investigational Site
RECRUITING

Montreal, Quebec, H2X 2V1, Canada
LEO Pharma Investigational Site
RECRUITING

Bad Bentheim, 48455, Germany
LEO Pharma Investigational Site
RECRUITING

Dresden, 01097, Germany
LEO Pharma Investigational Site
RECRUITING

Göttingen, 37075, Germany
LEO Pharma Investigational Site
RECRUITING

Kiel, 24105, Germany
LEO Pharma Investigational Site
RECRUITING

Lübeck, 23562, Germany
LEO Pharma Investigational Site
RECRUITING

Manheim, 68167, Germany
LEO Pharma Investigational Site
RECRUITING

Münster, 48149, Germany
LEO Pharma Investigational Site
RECRUITING

Osnabrück, 49074, Germany
LEO Pharma Investigational Site
RECRUITING

Witten, 58453, Germany
LEO Pharma Investigational Site
RECRUITING

Bialystok, 15-879, Poland
LEO Pharma Investigational Site
RECRUITING

Iwonicz-Zdrój, 38-440, Poland
LEO Pharma Investigational Site
RECRUITING

Lodz, 90-436, Poland
LEO Pharma Investigational Site
RECRUITING

Lublin, 20-011, Poland
LEO Pharma Investigational Site
RECRUITING

Rzeszów, 35-055, Poland
LEO Pharma Investigational Site
RECRUITING

Warsaw, 02-482, Poland
LEO Pharma Investigational Site
RECRUITING

Wroclaw, 50-556, Poland
LEO Pharma Investigational Site
RECRUITING

Wroclaw, 50-566, Poland
LEO Pharma Investigational Site
RECRUITING

Bristol, BS2 8HW, United Kingdom
LEO Pharma Investigational Site
RECRUITING

London, SE1 9RT, United Kingdom
LEO Pharma Investigational Site
RECRUITING

Newcastle upon Tyne, NE1 4LP, United Kingdom
LEO Pharma Investigational Site
RECRUITING

Salford, M6 8HD, United Kingdom
LEO Pharma Investigational Site
RECRUITING

Stourbridge, DY8 4JB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.